Carbohydrate Active Ingredients TRIZ Cases

Dapagliflozin targets SGLT2 to improve diastolic function, reduce fibrosis, and lower HFpEF hospitalization and cardiovascular risk.

Combining RXFP1 modulators with SGLT2 inhibitors extends therapeutic action and supports treatment of hypertension, heart failure, and CKD.

Combining a BET bromodomain inhibitor with an SGLT2 inhibitor addresses recurrent MACE risk after ACS, especially in type 2 diabetes.

Pairing zibotentan with dapagliflozin offsets fluid retention and hemoconcentration while improving CKD renal protection.

Modified monosaccharides use click chemistry and selective cellular assimilation to label cancer cells with low toxicity for detection and diagnosis.

Separate MR modulator and SGLT2 inhibitor pellets in one oral dose improve compatibility, flow, and compliance for HF and CKD treatment.

Dapagliflozin is used to treat HFpEF in diabetic and non-diabetic patients, improving diastolic function and lowering major cardiovascular events.

Combining zibotentan with dapagliflozin offsets fluid retention and volume depletion while improving renal protection in CKD.

Combining dapagliflozin with ACE-Is or ARBs addresses CKD progression while improving blood pressure and glycemic control.

Alternating tidal therapy and dwell phases use hypertonic solutions to improve toxin clearance and ultrafiltration without extra fluid or sorbents.

Dry and wet granule layers with colloidal silicon dioxide improve tablet stability and prevent capping, laminating, and separation.

Glycyrrhetinic acid suppresses inflammation and reverses fibrous tissue deposition to treat radiation-induced pulmonary fibrosis.

SGLT-2 inhibitors lower systolic blood pressure in cats and dogs, avoiding hypotension risks common with ACE inhibitor resistance.

Fluoride and amphotericin B combinations lower required dosages to treat fungal infections while minimizing nephrotoxicity risks.

Polysulfated oligosaccharides stimulate angiogenesis to accelerate closure of ischemic diabetic foot ulcers.

A composite adjuvant system links aluminum salts to C-type lectin receptor ligands via chemical bonds to enhance vaccine potency and stability.

8-Hydroxy quinoline derivatives inhibit repressor binding to the TERT promoter, increasing expression levels to delay cellular senescence.

Cationic liposomes encapsulate anticancer agents to deliver synergistic therapeutic effects while reducing adverse cardiac side effects.

Anti-Hsc70 inhibitors modulate host protein activity to suppress viral replication across multiple RNA virus families.

Replacing free base with tolterodine tartrate stabilizes the adhesive formulation and reduces skin irritation while preserving drug efficacy.

Exosome-encapsulated ACAT1 inhibitors stimulate autophagic clearance of misfolded proteins in microglia.

Hydrophilic matrix formers protect hygroscopic dapagliflozin from moisture absorption while maintaining rapid dissolution rates.

Incorporating a FIG4-derived 3'-untranslated region element into artificial nucleic acid molecules to enhance stability and prolong protein production.

Liposomal encapsulation maintains fixed cytarabine daunorubicin molar ratios, preventing differential clearance and reducing toxicity in leukemia treatment.

Sotagliflozin lowers hazard ratios for heart failure and stroke by targeting specific pathophysiology in non-hypertensive left ventricular hypertrophy.

SGLT-2 inhibitors delay disease progression and prolong survival time in dogs with myxomatous mitral-valve disease.

Amorphous dapagliflozin combined with specific excipients resolves the contradiction between stability and dissolution rate.

Labeled compositions bind to galectins to enable precise imaging, resolving the trade-off between measurement accuracy and system complexity.